File:13046 2019 1094 Fig5 HTML-Photoroom.webp
Size of this PNG preview of this WEBP file: 545 × 600 pixels. Other resolutions: 218 × 240 pixels | 436 × 480 pixels | 685 × 754 pixels.
Original file (685 × 754 pixels, file size: 30 KB, MIME type: image/webp)
Captions
Captions
cobimetinib
Summary
edit
| Description |
English: Mechanism of action of anti-BRAF drugs on the RAS signaling pathway. RAS activates both the CRAF and the BRAF pathways. Inhibitors for both BRAF and MEK are shown. These inhibitors act to prevent cell proliferation and growth of cancer cells. Sorafenib, vemurafenib, dabrafenib, cobimetinib, regorafenib, and trametinib are all FDA approved for the treatment of cancer |
| Date | |
| Source | https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1094-2 |
| Author | N. A. Seebacher, A. E. Stacy, G. M. Porter & A. M. Merlot |
Licensing
edit
This file is licensed under the Creative Commons Attribution 4.0 International license.
- You are free:
- to share – to copy, distribute and transmit the work
- to remix – to adapt the work
- Under the following conditions:
- attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
File history
Click on a date/time to view the file as it appeared at that time.
| Date/Time | Thumbnail | Dimensions | User | Comment | |
|---|---|---|---|---|---|
| current | 21:15, 16 May 2024 | | 685 × 754 (30 KB) | Ozzie10aaaa (talk | contribs) | Uploaded a work by N. A. Seebacher, A. E. Stacy, G. M. Porter & A. M. Merlot from https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1094-2 with UploadWizard |
You cannot overwrite this file.
File usage on Commons
There are no pages that use this file.
